Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug: report

A U.S. jury said on Monday that patents owned by Amgen Inc on its cholesterol drug Rapatha are valid, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA, Bloomberg reported.

from Reuters: Health News https://ift.tt/2NrlSTr